A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial For Evaluation Of The Efficacy And Safety Of Dkb114 On Reduction Of Uric Acid In Serum

NUTRIENTS(2020)

Cited 3|Views16
No score
Abstract
This study sought to investigate the antihyperuricemia efficacy and safety of DKB114 (a mixture of Chrysanthemum indicum Linn flower extract and Cinnamomum cassia extract) to evaluate its potential as a dietary supplement ingredient. This clinical trial was a randomized, 12-week, double-blind, placebo-controlled study. A total of 80 subjects (40 subjects with an intake of DKB114 and 40 subjects with that of placebo) who had asymptomatic hyperuricemia (7.0-9.0 mg/dL with serum uric acid) was randomly assigned. No significant difference between the DKB114 and placebo groups was observed in the amount of uric acid in serum after six weeks of intake. However, after 12 weeks of intake, the uric acid level in serum of subjects in the DKB114 group decreased by 0.58 +/- 0.86 mg/dL and was 7.37 +/- 0.92 mg/dL, whereas that in the placebo group decreased by 0.02 +/- 0.93 mg/dL and was 7.67 +/- 0.89 mg/dL, a significant difference (p = 0.0229). In the analysis of C-reactive protein (CRP) change, after 12 weeks of administration, the DKB114 group showed an increase of 0.05 +/- 0.27 mg/dL (p = 0.3187), while the placebo group showed an increase of 0.10 +/- 0.21 mg/dL (p = 0.0324), a statistically significant difference (p = 0.0443). In the analysis of amount of change in apoprotein B, after 12 weeks of administration, the DKB114 group decreased by 4.75 +/- 16.69 mg/dL (p = 0.1175), and the placebo group increased by 3.13 +/- 12.64 mg/dL (p = 0.2187), a statistically significant difference between the administration groups (p = 0.0189). In the clinical pathology test, vital signs and weight measurement, and electrocardiogram test conducted for safety evaluation, no clinically significant difference was found between the ingestion groups, confirming the safety of DKB114. Therefore, it may have potential as a treatment for hyperuricemia and gout. We suggest that DKB114 as a beneficial and safe food ingredient for individuals with high serum uric acid. Trial registration (CRIS.NIH. go. Kr): KCT0002840.
More
Translated text
Key words
dietary supplements, asymptomatic hyperuricemia, DKB114, Chrysanthemum indicum Linn, Cinnamomum cassia, clinical trial, uric acid
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined